Introduction
Increased miR-21 levels have been shown in various types of solid tumors as well as in hematological malignancies [1] [2] [3] [4] [5] [6] . Consistent with the marked overexpression in cancer, several studies showed an antiapoptotic effect of miR-21. Knockdown of miR-21 correlates with increased apoptosis and reduced proliferation of breast cancer cells [2, 3] . Multiple cancerrelevant miR-21 target genes, such as tropomyosin 1 (TPM1), programmed cell death 4 (PDCD4), phosphatase and tensin homolog (PTEN), Maspin, and SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), have been identified [4] [5] [6] [7] [8] [9] . More recent studies also showed effects of miR-21 on T-cell activation and survival [10] [11] [12] [13] . We previously showed that memory T cells are characterized by a high expression of miR-21. In addition, we showed that activation-induced miR-21 provides critical antiapoptotic signals in memory T cells allowing long-term survival [11, 14] . However, the miR-21 target genes responsible for the protection against activation-induced apoptosis of T cells remain unknown.
In this study, we set out to investigate miR-21 target genes related to its antiapoptotic effects on T cells. We employed an experimental RNA-immunoprecipitation followed by gene expression microarray (RIP-Chip)-based approach [15] in Jurkat cells. These cells are a commonly used model to study regulatory pathways involved in T-cell activation and apoptosis. We identified the proapoptotic large tumor suppressor kinase 1 (LATS1) as the miR-21 target gene whose enrichment in the argonaute 2 immunoprecipitated (AGO2-IP) increased the most upon miR-21 overexpression and showed its role in the antiapoptotic effect of miR-21.
Results and discussion
Jurkat is a suitable model to study the antiapoptotic role of miR-21
To assess if the Jurkat cell line is a suitable model to study the function of miR-21 in relation to apoptosis, we determined miR-21 expression levels in unstimulated cells and after stimulation with aCD3/aCD28. In comparison to other miRNAs known to be expressed in T cells at high (miR-17) or low (miR-146a) levels, miR-21 levels were moderate in unstimulated cells (Fig. 1A) . Activation of Jurkat cells with aCD3/ aCD28 for 3 days revealed a marked induction of miR-21 expression (≥25-fold, P ≤ 0.001; Fig. 1B ) consistent with previous studies on aCD3/aCD28-stimulated primary T cells [11, 13] . To determine whether loss of miR-21 resulted in a growth defect, we infected Jurkat cells with a miR-21 inhibitor vector which coexpresses GFP. GFP analysis over time of a mixture of transduced and nontransduced cells (GFP competition assay) revealed a significant decrease of miR-21 inhibitor-transduced (GFP-positive) cells when compared to nontransduced (GFP-negative) cells (Fig. 1C ). Cells transduced with three nontargeting (NT) control inhibitors showed no effect on cell growth in the GFP competition assay (Fig. 1C and data not shown). Jurkat cells transduced with miR-21 inhibitor showed a significant decrease of viable cells starting at day 4, which was not observed with control transduced cells (Fig. 1D ). This effect was paralleled by an increase of apoptotic cells reaching > 80% at day 6 (Fig. 1E,F) . These findings are consistent with our reported findings in primary T cells [11] and indicate that endogenous levels of miR-21 in Jurkat cells provide an essential antiapoptotic signal. Together, these data show that the Jurkat cell line is a suitable model to study the antiapoptotic properties of miR-21 in T cells.
miR-21 target genes involved in apoptosis
To identify the antiapoptotic miR-21 target genes, we performed AGO2-RIP-Chip on Jurkat cells overexpressing miR-21 (Jurkat-miR-21) and used cells transduced with an empty vector construct (Jurkat-EV) as a control. The miR-21 levels showed an increase of 22-fold in Jurkat-miR-21 compared to Jurkat-EV ( Fig. 2A) . Overexpression of miR-21 in Jurkat cells did not cause any obvious effects on the percentage of live cells (data not shown). The efficiency of the AGO2 immunoprecipitation (AGO2-IP) as determined by western blot was comparable between Jurkat-EV and Jurkat-miR-21 cells (Fig. 2B) . As expected, miR-21 was strongly enriched in the Jurkat-miR-21 AGO2-IP fraction in comparison to the Jurkat-miR-21 total fraction and the Jurkat-miR-21 and Jurkat-EV IgG1 control IP fractions. Some miR-21 enrichment could also be observed in the Jurkat-EV AGO2-IP fraction as Jurkat cells endogenously express moderate miR-21 levels (Figs. 2C and 1A) .
Gene set enrichment analysis (GSEA) [16] revealed a strong enrichment of multiple microRNA (miRNA)-binding motifs in both Jurkat-miR-21 (8 of the top 10) and Jurkat-EV (9 of the top 10, Table 1 ) further validating the efficiency of the AGO2-RIP. The miR-21-binding motif increased from the 46th position of most enriched gene sets in Jurkat-EV (false discovery rate (FDR) = 0.0013) to the 28th position in Jurkat-miR-21 cells (FDR ≤ 0.001). Comparison of both top-10 enriched gene sets revealed a marked overlap between Jurkat-miR-21 and Jurkat-EV cells with eight shared gene sets (Table 1) . A marked difference was observed for two apoptosis-related gene sets. Genes regulated upon treatment with the growth and survival factor, IL-6, were among the top-10 most enriched gene sets in Jurkat-EV but not in Jurkat-miR-21 (position 258). Genes involved in sensitivity to TRAIL-induced apoptosis were found among the top-10 most enriched in Jurkat-miR-21 but not in Jurkat-EV cells (position 1237). The expression levels of genes represented by the latter gene set showed an overall decrease in the total fraction of Jurkat-miR-21 as compared to Jurkat-EV (not shown). These differences can be explained by either direct or indirect effects of miR-21 and fit with the observed antiapoptotic role of miR-21 in Jurkat cells. Comparison of the expression levels of all predicted miR-21 target genes (209 of 14 514 unique genes) between the total fractions of Jurkat-EV and Jurkat-miR-21 revealed a systematic decrease in transcript levels in Jurkat-miR-21 cells (Fig. 3A) . This indicates that transcript levels of predicted miR-21 genes were decreased upon miR-21 overexpression. As a control, we also analyzed differences in the expression levels of predicted miR-146a targets (162 of 14 514) and predicted miR-17 targets (929 of 14 514).
No difference was observed for the predicted miR146a target genes, while a mild decrease was observed for predicted miR-17 target genes (Fig. 3A) . The latter observation can be explained by the marked overlap between the miR-21 and miR-17 predicted target genes, i.e., 62 shared predicted target genes. In line with these observations, we noted a specific enrichment of predicted miR-21 target genes among the top-1500 genes enriched in the IP of Jurkat-miR-21 (n = 72) as compared to the IP of Jurkat-EV cells (n = 48). The enrichment was even more pronounced among the top-250 enriched genes (n = 20 versus n = 10; Fig 3B) .
As a control, we also analyzed enrichment of the predicted target genes of miR-146a and miR-17, which revealed no differences between Jurkat-EV and JurkatmiR-21 (Fig. 3B) . Together, these data show an efficient enrichment of miRNA target genes in the IP fractions of both conditions and a marked enrichment of miR-21 predicted target genes in Jurkat cells overexpressing miR-21.
LATS1 is involved in the antiapoptotic role of miR-21 in T cells
Seventy-two predicted miR-21 targets were enriched at least twofold in Jurkat-miR-21 IP as compared to the total fraction. Seventy-one of these 72 targets were AGCACTT, miR-93, miR-302A, miR-302B, miR-302C, miR-302D, miR-372, miR-373, miR-520E, miR-520A, miR-526B, miR-520B, miR-520C, miR-520D 2 1
TGAATGT, miR-181A, miR-181B, miR-181C, miR-181D 9 2 GCACTTT, miR-17-5P, miR-20A, miR-106A, miR-106B, miR-20B, miR-519D Table 1 . Gene set enrichment analysis.
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The enriched at least twofold more in the AGO2-IP fraction of Jurkat-miR-21 as compared to the AGO2-IP fraction of Jurkat-EV. These 71 targets and their gene ontologies are listed in Table 2 and include 11 previously confirmed miR-21 target genes (at least by reporter assay). Of these 11, we validated the regulation of PIK3R1 by miR-21 using luciferase assays and the upregulation of PDCD4 protein expression upon miR-21 inhibition in Jurkat cells (data not shown). Within the 71 target genes identified in this study, six were related to regulation of apoptosis, i.e., PDCD4, Ras homology family member B (RHOB), mitogen-activated protein kinase 1 (MAP3K1), protein kinase C (PRKCE), RAS P21 protein activator (GTPase-activating protein) 1 (RASA1), and LATS1. We selected LATS1 for further studies as it showed the strongest increase in AGO2-IP enrichment upon miR-21 overexpression (Table 2) and had a known function related to apoptosis [17, 18] . In addition, it was recently shown that miR-21 can target LATS1 in cervical cancer [19] . We identified one 8-mer and two 7-mer miR-21-binding sites in the 3 0 UTR of LATS1 (Fig. 4A ). Luciferase reporter assays with two constructs including either the 8-mer or the two 7-mer miR-21-binding sites consistently showed significant increases in luciferase activity, thereby demonstrating that LATS1 is a bona fide miR-21 target (Fig. 4B ). In agreement with this finding, inhibition of miR-21 in Jurkat cells increased the expression of LATS1 protein (Fig. 4C) .
To determine the relevance of the increase of LATS1 for the miR-21 inhibition-induced phenotype (Fig. 1C) , we studied the effect of miR-21 inhibition in LATS1-knockdown (KD) cells. Stable LATS1-KD cells were generated by infection of Jurkat cells with lentiviral LATS1-shRNA constructs or NT control shRNA vectors. Western blotting for LATS1 in sorted LATS1-KD cells showed that the efficiency of the shRNAs ranged between 70% and 90% (Fig. 5A) . Next, we infected the LATS1-KD and control cells with miR-21 inhibitor and control inhibitor virus, containing GFP and monitored the GFP percentage over time within the LATS1-KD cells. As expected, miR-21 inhibition caused a strong reduction in the percentage of GFP+ cells in the NT shRNA-infected and wild-type cells with on average 15% of GFP+ cells left after 22 days (Fig. 5B) . Knockdown of LATS1 was found to partially rescue this effect as a more than 2.5-fold higher percentage of GFP+ cells was left (average of the three shRNAs, 38%) after 22 days of miR-21 inhibition (P-value ≤ 0.05, Fig. 5B ). These results show that the proapoptotic effect observed upon miR-21 inhibition is at least in part mediated by downregulation of LATS1.
To study the relevance of the miR-21-LATS1 axis in primary T cells, we analyzed LATS1 and miR-21 levels of primary sorted na€ ıve T cells (CD4+CD45RO-) stimulated for 3 days with a-CD3 and a-CD28. This revealed an inverse pattern, i.e., increased levels of miR-21 and decreased levels of LATS1 upon stimulation (Fig. 6A,  B) . The increase of miR-21 upon stimulation supports our previous findings and those of others [11] [12] [13] 20] . The inverse expression pattern of LATS1 suggests that targeting of LATS1 by miR-21 is highly relevant for survival of primary T cells. We also studied miR-21 and LATS1 expression in sorted na€ ıve (CD4+CD45RO-) and memory (CD4+CD45RO+) T cells. In line with what we and others have previously shown, we observed higher levels of miR-21 in memory T cells compared to na€ ıve T cells (Fig. 6C) [11, 12, 20] . However, we did not observe decreased LATS1 transcript levels in memory T cells as compared to na€ ıve T cells (Fig. 6D) . This suggests that miR-21 does not lower the LATS1 RNA levels in memory cells, but regulates LATS1 protein level by post-transcriptional repression of protein translation. To confirm regulation of LATS1 protein levels by miR-21 specifically in memory T cells, LATS1 protein analysis in na€ ıve and memory T cells as well as AGO2-RIP experiments should be performed.
In summary, we showed that the Jurkat cell line is a suitable model to study the role of miR-21 in the regulation of T-cell apoptosis. We experimentally identified multiple miR-21 target genes via employing AGO2-RIP-Chip, including the proapoptotic LATS1 gene. We showed that LATS1 is a bona fide miR-21 target whose knockdown can at least partially rescue the proapoptotic effect of miR-21 inhibition. Thus, LATS1 is likely to be an important target for the antiapoptotic role of miR-21 in (activated) T cells, possibly in combination with other targets such as PDCD4. As miR-21 is widely overexpressed in a variety of cancers, it is also of interest to further study the relevance of the miR-21 target LATS1 in relation to cancer. 
Materials and methods

Cell lines
The Jurkat, human acute leukemic T-cell line was cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 200 mM L -glutamine, 100 mM Na-pyruvate, 10 mgÁmL À1 gentamycin (Lonza, Breda, The Netherlands), Cell lines were obtained from ATCC. We routinely confirmed the identity of our cell lines using the PowerPlex 16 HS System (Promega, Leiden, The Netherlands).
T-cell activation with aCD3/aCD28 monoclonal antibodies (mAbs)
Stimulation of Jurkat T cells was performed with platebound anti-CD3 and soluble anti-CD28 mAbs. Briefly, culture plates were incubated with goat anti-mouse-IgG2a Ab (Cat. No. 1080-01, Southern Biotechnology, Uden, The Netherlands) overnight at 4°C, followed by washing with PBS and 1-h incubation with hybridoma-culture supernatant, containing anti-human-CD3 IgG2a mAb (clone WT32, concentration~1 lg IgGÁmL were harvested, lyzed with Qiazol reagent (Qiagen, Venlo, The Netherlands), and stored at À20°C. Primary CD4+ Tcell isolation and stimulation was described earlier [20, 21] . All participants provided written informed consent according to the Declaration of Helsinki to participate in this study which was approved by The Medical Ethical Committee (METC; project number: 2009.118) of the University Medical Center Groningen UMCG.
Viral constructs
To generate the lentiviral miR-21 overexpression construct, pre-miR-21 with~150 nucleotides of the flanking sequence was amplified from genomic DNA using forward 5 0 -gtcagaatagaatagaattgggg-3 0 and reverse 5 0 -gctgcattatggcacaaaag-3 0 primers. NheI and XhoI restriction sites were added to the forward primer and an EcoRI site was added to the reverse primer to allow directional cloning into the retroviral MXW-PGK-IRES-GFP vector [22] using standard laboratory procedures. To stably inhibit miR-21 function, we used a lentiviral miR-21 inhibition vector (pmiRZip-21; Cat. Nr: MZIP21-PA-1) and three NT lentiviral inhibitor vectors (control inhibitor, Cat. Nr: MZIP000-PA-1, both from Systems Biosciences, Mountain View, USA and shNT1 and shNT2, see below) as controls. The sequences of shRNAs against LATS1 and controls used for cloning to the BamHI and EcoRI sites of the lentiviral pDsREDPuro vector (MZIP/pGreenPuro vector with the copGFP replaced by dsRED, Systems Biosciences) are as follows: LATS1-sh1-S: 5 0 GATCCGCTGCTCCT TCGTCATATACATTCAAGAGATGTATATGACGAAGG 
Virus production and viral transduction
Lentiviral particles were produced with a third-generation lentiviral system in 293T cells by CaPO 4 transfection as described previously [23] . Lentiviral transduction of Jurkat cells was carried out for 24 h in the presence of 4 lgÁmL 
GFP competition assay
GFP percentage of pmiRZip-21-or pmiRZip-scrambledinfected Jurkat cells was followed over a period of 22 days. The starting GFP percentage varied between 30% and 40%. Data were acquired on FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using FLOWJO software (version 7.6, Treestar, Ashland, OR, USA). The GFP percentage analyzed at the first day of measurement (day 4) was set to 1. The GFP competition assay was performed 3 times.
Apoptosis measurement
Percentages of apoptotic cells were assessed in Jurkat cells transduced with miR-21 or control inhibitor in > 95% of the cells on day 4, 6, and 8 following viral transduction by FACS-based measurement of mitochondrial transmembrane potential loss. Briefly, cells were stained for 20 min at 37°C in cell culture medium containing 50 nM DiLC1 (Enzo Life Sciences, NY, USA), which was followed by a washing step with PBS. Cells were kept on ice and DiLC1 staining was measured at the FACS Calibur flow cytometer using Cell Quest software (BD Biosciences). Data were analyzed using Kaluza Flow Analysis Software (Beckman Coulter).
Quantitative RT-PCR
Total cellular RNA was extracted using the miRNeasy Mini Kit (Qiagen) following the manufacturer's instructions. The RNA quantity was measured on a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific).
MicroRNA expression levels were determined by quantitative RT-PCR. RNA was reverse transcribed using the Taqman miRNA Reverse Transcription kit in combination with multiplexed reverse transcription primers of TaqMan miRNA assays (Thermo Scientific): for miR-21-5p (ID: 000397), miR-17 (ID: 002308), miR-146a (ID: 000468), RNU48 (ID: 001006), RNU44 (ID: 001094) [24] . RNU44 and 48 served as reference genes to normalize miRNA expression levels. The qPCR reaction was performed using qPCR MasterMix Plus (Eurogentec, Liege, Belgium).
cDNA synthesis for mRNA was performed using Superscript III RTase (Thermo Scientific). The qPCR reaction was performed using qPCR MasterMix Plus. 
AGO2-RIP-Chip procedure
Immunoprecipitation of AGO2-containing RISC complexes was performed as described previously by Tan et al. [15] and Slezak-Prochazka et al. [25] . Briefly, cleared lysates of 40 million cells were incubated with protein G Sepharose beads (GE Healthcare, Eindhoven, The Netherlands) coated with anti-AGO2 antibody (Clone 2E12-1C9, Abnova, Taiwan) at 4°C overnight. IP with anti-IgG antibody was used as a negative control (Millipore BV, Amsterdam, The Netherlands). After washing the beads, RNA was harvested for microarray and qRT-PCR analysis and protein lysates were prepared for western blot. RNA from total (sample taken before start of the IP procedure), flow through (FT; sample taken of the supernatant after collection of the IP fraction), and IP fractions was isolated with miRNeasy Mini kit (Qiagen) according to the manufacturer's protocol. RNA from total and AGO2-IP fractions of Jurkat-miR-21 and Jurkat-EV cells was used for microarray analysis. Labeling and hybridization were performed using two-color Low Input Quick Amp Labeling Kit, according to the manufacturer's protocol (Agilent, Santa Clara, USA). Briefly, 40-100 ng of RNA from T and AGO2-IP samples was used for cDNA synthesis, followed by cRNA amplification and Cy-3 and Cy-5 labeling. cRNA was purified with RNeasy Kit (Qiagen) and quantified on NanoDrop TM ND-1000 Spectrophotometer (Thermo Scientific). Equal amounts of cRNA Cy-3 and Cy-5-labeled samples were combined and hybridized at 65°C for 17 h on the 60k SurePrint G3Human Whole Genome Oligo Microarray (Agilent). Next, slides were washed and scanned with SureScan Dx Microarray Scanner (Agilent). Scanned images were used for Agilent Feature Extraction software version 10.5, converted into Linear and Lowess normalized data. Quality control report was generated for each array. Using GeneSpring GX version 12.5 (Agilent), quantile normalization of the signals was performed. Next, probes not detected in more than half of the samples and probes that are inconsistent (more than twofold different) in Cy-3 and Cy-5 replicates of the same sample were filtered out. The averaged signals for Cy-3 and Cy-5 replicates were used to calculate the IP/T ratio for each sample. The microarray data have been deposited in NCBI's Gene Expression Omnibus (GSE85116).
Western blotting
Cells were lyzed in Cell Lysis buffer (Cat. # 9803, Cell Signaling Technologies, Leiden, The Netherlands) and incubated on ice for 45 min, centrifuged at 14 000 g, 4°C and supernatant was collected. Protein concentration was determined using DC Protein Assay following the manufacturer's instructions (Bio-Rad Laboratories, Hercules, USA). Samples were separated on 10% polyacrylamide gels and transferred onto nitrocellulose membranes. Membranes were blocked using Odyssey blocking buffer (LI-COR Biosciences, Nebraska, USA). For the detection of LATS1, rabbit polyclonal anti-human-LATS1 antibody (ab 70562; Abcam, Cambridge, UK) was used in a dilution of 1 : 250 and incubated overnight at 4°C. LATS1 expression was visualized with secondary polyclonal antibody goat antirabbit peroxidase (GaRPO) 1 : 1000 incubated at RT for an hour (Dako, Leuven, Belgium) and a tertiary rabbitanti-goat peroxidase (RAGPO) incubation step (1-h incubation, 1 : 1000 at RT; Dako). The GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, USA) was used in a 1 : 20 000 dilution and staining was visualized with secondary polyclonal rabbit-anti-mouse peroxidase (RaMPO, 1 : 1000). All antibodies were diluted in Odyssey blocking buffer supplemented with 0.1% Tween-20. Immunoblots were incubated with primary antibodies at 4°C overnight. Secondary polyclonal goat anti-mouse antibody conjugated with IRdye 680, and polyclonal goat anti-rabbit antibody conjugated with IRdye 800 (both from LI-COR Biosciences) were used. Signal was detected with the Odyssey Infrared Imaging System, Odyssey CLx, and protein bands were visualized and quantified with IMAGE STUDIO software version 2.0.38 (both from LI-COR Biosciences). Western blot for AGO2 was performed as described previously [25] .
Cloning of 3
0 -UTRs in reporter constructs, transient transfection, and luciferase assays Madison, USA), as previously described [26] . The inserts were sequence verified (BaseClear, Leiden, The Netherlands). About 1.2 9 10 4 Cos-7 cells were transfected with 125 ng of the psiCHECK2 construct and 50 nM miR-21 inhibitor, molecule ID: 4102261-101 or Negative Control #1 inhibitor, (Exiqon, Vedbaek, Denmark), using the Saint-MIX compound (Synvolux Therapeutics B.V., Groningen, The Netherlands), in 250 ll serum-free medium. Four hours following the transfection, 500 ll of medium supplemented with 10% FBS was added. Cells were lysed 24 h after transfection, and Renilla and firefly luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Leiden, The Netherlands) according to the manufacturer's instructions. For each transfection, luciferase activity was measured in duplicate with the Luminoscan Ascent Microplate Luminometer (Thermo Scientific). The renilla (RL) over firefly (FF) luciferase ratio for miR-21 inhibitor was calculated. The RL/FF ratio of negative control was set to a value of 1. Transfections were performed in triplicate.
Prediction of miRNA target genes
The miRNA target prediction program TARGETSCAN 6.2 (http://www.targetscan.org/) was used to determine predicted target genes of miR-21 (307 conserved genes), miR146a (224 conserved genes), and miR-17 (1.220 conserved genes).
Functional annotation analysis
The functional annotation of genes was performed using the DAVID BIOINFORMATIC RESOURCES 6.7 (https://david.ncifcrf. gov/), based on the following GO categories: GOTERM_BP_-FAT, GOTERM_CC_FAT, GOTERM_MF_FAT, KEGG_-PATHWAY, and SP_PIR_KEYWORDS. About 1-4 GO terms were considered for description of each gene.
Gene set enrichment analysis
Gene sets significantly enriched in the AGO2-IP in comparison to T fraction of Jurkat-EV and Jurkat-miR-21 were determined by the GSEA using the Molecular Signatures Database (GSEA; http://software.broadinstitute.org/gsea/ index.jsp) [16] . Lists containing the expression values of 14 415 genes detected in IP and total fractions of Jurkat-EV or Jurkat-miR-21 were uploaded for the analysis. 
Statistical analysis
